Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Price Target at $12.33

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $12.3333.

A number of research analysts recently commented on DMAC shares. Wall Street Zen raised DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 4th. Lake Street Capital increased their price target on DiaMedica Therapeutics from $11.00 to $14.00 and gave the company a “buy” rating in a report on Friday, July 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a report on Friday, August 15th. Finally, Craig Hallum boosted their price objective on DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a report on Friday, July 18th.

Insiders Place Their Bets

In other news, major shareholder Jan Stahlberg acquired 50,772 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average cost of $6.00 per share, with a total value of $304,632.00. Following the completion of the acquisition, the insider directly owned 7,764,465 shares in the company, valued at $46,586,790. This represents a 0.66% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders bought 1,000,000 shares of company stock valued at $5,958,598 over the last three months. 7.30% of the stock is owned by insiders.

Institutional Trading of DiaMedica Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DMAC. World Investment Advisors increased its holdings in DiaMedica Therapeutics by 17.0% in the first quarter. World Investment Advisors now owns 25,650 shares of the company’s stock valued at $97,000 after buying an additional 3,735 shares during the last quarter. Royal Bank of Canada lifted its holdings in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after acquiring an additional 154,701 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in DiaMedica Therapeutics by 76.7% in the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock worth $462,000 after acquiring an additional 52,854 shares during the last quarter. Jane Street Group LLC lifted its holdings in DiaMedica Therapeutics by 138.5% in the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock worth $382,000 after acquiring an additional 58,457 shares during the last quarter. Finally, Perigon Wealth Management LLC bought a new position in DiaMedica Therapeutics in the second quarter worth about $207,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Stock Performance

Shares of DMAC opened at $6.65 on Thursday. The company has a market capitalization of $343.73 million, a P/E ratio of -9.64 and a beta of 1.40. DiaMedica Therapeutics has a one year low of $3.19 and a one year high of $7.49. The stock has a 50-day moving average price of $6.72 and a 200 day moving average price of $5.16.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). As a group, equities research analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.